Showing 2291-2300 of 5644 results for "".
- Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseaseshttps://modernod.com/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001-for-retinal-diseases/2481256/Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-relat
- Bloomberg: Novartis Considering Sale of Ophthalmology Unithttps://modernod.com/news/bloomberg-novartis-considering-sale-of-ophthalmology-unit/2481246/Novartis is considering selling its non-core assets, including its ophthalmology franchise, to raise money for cutting-edge medicines, according to a Bloomberg
- Study: Vision Impairment is Associated with as Many as 100,000 US Dementia Caseshttps://modernod.com/news/study-vision-impairment-is-associated-with-as-many-as-100000-us-dementia-cases/2481238/Up to 100,000 US dementia cases could have potentially been prevented with improved eye care, according to a National Institute on Aging (NIA)-funded study published in JAMA Neurology. While the search for breakthrough drugs or interventions that could be treatments f
- FDA Accepts Tarsus' New Drug Application for TP-03 for Treatment of Demodex Blepharitishttps://modernod.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/As part of its third quarter earnings report, Tarsus Pharmaceuticals announced that the FDA has accepted the company's new drug application (NDA) for TP-03 for the treatment of Demodex blepharitis. The Prescription Drug User Fee Act (PDUFA) target action da
- Aviceda Announces Additional Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmologyhttps://modernod.com/news/aviceda-announces-additional-members-to-its-clinical-advisory-board-to-support-its-clinical-development-strategy-in-ophthalmology/2481232/Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators, announced the addition of ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are:
- Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patientshttps://modernod.com/news/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectiveness-of-the-omni-surgical-system-in-pseudophakic-glaucoma-patients-with-uncontrolled-pressure-following-a-previous-combination-cataract-stent-procedure/2481221/Sight Sciences announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophaki
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- EyeCare Partners Expands Footprint in Northern Ohio with Three Additional Practiceshttps://modernod.com/news/eyecare-partners-expands-footprint-in-northern-ohio-with-three-additional-practices/2481171/EyeCare Partners announced that it has expanded its presence in Northern Ohio through a partnership with Novus Clinic, Corrective Eye Center, and Retina Specialists of Ohio (RSO). Additionally, the company plans to build a new Ambulatory Surgery Center (ASC) as well as a 16-exam lane clinic,
- SpyGlass Pharma Presents 3-Month Data from the First-In-Human Trial of Its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-presents-3-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481140/SpyGlass Pharma announced 3-month data from a first-in-human glaucoma treatment trial showing that its breakthrough drug delivery platform lowered IOP in patients with open-angle glaucoma or ocular hypertension. The data were showcased during an oral presentation at the Eyecelerator inn